Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Filbert who wrote (1358)	10/8/1998 12:49:00 PM
From: yosi s	Respond to of 1491

To all Omer posted a great comprehensive review. all the latest numbers are there. www.ariga.com/omer

To: Filbert who wrote (1358)	10/8/1998 2:38:00 PM
From: Rick Strange	Read Replies (1) \| Respond to of 1491

In one of the interviews Par's Chairman mentioned that they were in discussion with several potential partners regarding HU-211 "pending results from the final cohort." Achieving statistically significant lower ICP pressure is amazing when you consider the small sample size. Other benefits of HU-211, though not statistically significant, show very strong trends that will in all probability be verified with a larger trial...maybe even once the third cohort is completed. If this were a game of stud poker, potential partners are looking across the table at PAR's hand with a couple of aces showing. Let's take our time and grow the pot.